This technology repurposes the FDA-approved anti-IL-17RA monoclonal antibody Brodalumab for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy.
Current management of immune-related adverse events relies largely on corticosteroids and broad immunosuppressive therapies that can compromise anti-tumor immunity, increase infection risk, and limit continued immunotherapy treatment. As immune checkpoint inhibitors become standard of care across multiple cancer types, there is a growing need for more targeted approaches to control irAEs while maintaining cancer-fighting immune activity.
This technology repurposes Brodalumab, an FDA-approved anti-IL-17 receptor A monoclonal antibody, for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. By inhibiting IL-17-mediated inflammation, Brodalumab provides a targeted approach to reducing inflammatory toxicities while preserving anti-tumor immune responses. Potential applications include treatment of checkpoint inhibitor-induced colitis, dermatitis, arthritis, pneumonitis, and other inflammatory complications.
Patent Pending(US20260015428)
IR CU23267
Licensing Contact: Cynthia Lang